Organisation paid for research Program year 2024 Source: CMS Open Payments

Clinilabs

Neither a doctor nor a teaching hospital

Research payments

$1,571,480

62 payments

Through program year 2024, Clinilabs is reported as receiving $1,571,480 in research payments, across 62 payments.

By program year

5 rows
Year Kind Amount Payments
2024 Research $55,328 2
2023 Research $5,345 6
2021 Research $1,299,745 49
2020 Research $113,042 4
2019 Research $98,019 1

Breakdown

Who paid Research payments · program years 2019–2024
  1. Takeda Pharmaceuticals U.S.A., Inc. $1,409,516 51 payments
  2. Novartis Pharmaceuticals Corporation $156,119 4 payments
  3. H. Lundbeck A S $2,850 5 payments
  4. Pfizer Inc. $2,495 1 payment
  5. Merck Sharp & Dohme Corporation $500 1 payment
Studies the money was for Research payments · program years 2019–2024
  1. A Randomized, Double-Blind, Placebo-Controlled, 3-Period Crossover Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of Oral Tak-994 in An Acute Sleep Phase Delay Paradigm in Healthy Male Subjects $1,299,745 49 payments
  2. A Randomized, Double-Blind, Placebo-Controlled, 3-Period Crossover Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of Oral Tak-994 in An Acute Sleep Phase Delay Paradigm in Healthy Male Subjects $109,771 2 payments
  3. A Randomized Subject and Investigator Blinded Placebo Controlled Study to Assess the Safety Pharmacokinetics and Efficacy of Intravenous Bimagrumab in Obese Patients With Type 2 Diabetes $100,790 2 payments
  4. A Randomized, Participant and Investigator Blinded, Sponsor Open-Label, Placebo-Controlled, Single Dose Study to Investigate the Safety and Tolerability of Xxb750 in Heart Failure Participants With Reduced Ejection Fraction (Hfref) $35,278 1 payment
  5. A multi-center, randomized, double-blind placebo-controlled and open-label active-controlled, parallel-group, 24-week proof of concept and dose-finding study to evaluate efficacy, safety, and tolerability of XXB750 in patients with heart failure $20,050 1 payment
  6. Study With Lu Af87908 in Healthy Participants and Participants With Alzheimer's Disease $2,850 5 payments
  7. A Phase 3 Multicenter Placebocontrolled Randomized Observerblinded Trial to Evaluate the Efficacy Safety Tolerability Immunogenicity and Lot Consistency of A 6Valent Ospabased Lyme Disease Vaccine in Healthy Participants 5 Years of Age $2,495 1 payment
  8. A Phase 2a, Randomized, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of MK-1942 Added to Stable Antidepressant Therapy in Participants With Treatment-Resistant Depression $500 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2024

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record